Please ensure Javascript is enabled for purposes of website accessibility

AstraZeneca Starts Clinical Trial Testing Its COVID-19 Treatment Antibody Cocktail

By Brian Orelli, PhD – Aug 25, 2020 at 6:18PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The U.K.-based drugmaker is hedges its bets with AZD7442.

All eyes are on AstraZeneca's (AZN 0.40%) coronavirus vaccine AZD1222, which is in late-stage testing and could be on the market in October.

But the U.K.-based pharma is still hedging its bets, launching a phase 1 clinical trial for AZD7442, a treatment for COVID-19.

AZD7442 is a mixture of two antibodies that were isolated from patients infected with SARS-CoV-2, the coronavirus that causes COVID-19. AZD7442 is manufactured in a plant, unlike convalescent plasma that received an emergency use authorization on Sunday, which is collected from plasma of recovered patients. The purity of AZD7442 will increase the consistency of the product, but there are no guarantees the two antibodies AstraZeneca picked will block the virus in patients.

AstraZeneca will initially test AZD7442 in 48 healthy volunteers before moving the product into larger phase 2 and phase 3 studies, assuming the treatment is safe and tolerable. In addition to being used as a treatment for infected patients, AZD7442 could also be used as a preventative measure in patients who had been exposed to people infected with the coronavirus.

Doctor in personal protective equipment talking to a patient

Image source: Getty Images.

AZD7442 trails Regeneron Pharmaceuticals' (REGN -1.93%) two-antibody-cocktail REGN-COV2, which is being tested in two phase 2/3 clinical trials for the treatment of COVID-19 and in a single phase 3 study for the prevention of COVID-19 in household contacts of infected individuals. The biotech recently teamed up with Roche (RHHBY -1.53%) to help increase production and distribution of REGN-COV2, assuming it gains regulatory approval.

AstraZeneca's phase 1 study is being funded by the U.S. Defense Advanced Research Projects Agency and the U.S. Biomedical Advanced Research and Development Authority, so even if AZD7442 isn't needed because one or more of the vaccines and/or REGN-COV2 are largely successful, the hedge won't cost the drugmaker much.

Brian Orelli, PhD and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$54.91 (0.40%) $0.22
Roche Holding AG Stock Quote
Roche Holding AG
RHHBY
$41.11 (-1.53%) $0.64
Regeneron Pharmaceuticals, Inc. Stock Quote
Regeneron Pharmaceuticals, Inc.
REGN
$691.82 (-1.93%) $-13.60

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
342%
 
S&P 500 Returns
107%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.